Details for Patent: 7,696,162

Title:	Zinc-free and low-zinc insulin preparations having improved stability
Abstract:	The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations.
Inventor(s):	Boderke; Peter (Frankfurt am Main, DE)
Assignee:	Sanofi-Aventis Deutschland GmbH (Frankfurt am Main, DE)
Filing Date:	Oct 06, 2008
Application Number:	12/285,464
Claims:	1. A formulation comprising: Lys(B3),Glu(B29) human insulin; a compound chosen from polysorbate 20, polysorbate 80, and poloxamer 171; and water, wherein the formulation is free from zinc or contains less than 0.2% by weight of zinc based on the insulin content of the formulation. 2. The formulation according to claim 1, wherein the pH is in a range from 6 to 8.5. 3. The formulation according to claim 1, wherein the formulation further comprises tromethamine. 4. The formulation according to claim 1, wherein the formulation further comprises NaCl. 5. The formulation according to claim 1, wherein the formulation further comprises cresol. 6. The formulation according to claim 5, wherein the formulation further comprises tromethamine. 7. The formulation according to claim 6, wherein the formulation further comprises NaCl. 8. The formulation according to claim 1, wherein the compound is polysorbate 20. 9. A method of treating diabetes mellitus comprising administering a formulation comprising: Lys(B3),Glu(B29) human insulin; a compound chosen from polysorbate 20, polysorbate 80, and poloxamer 171; and water, wherein the formulation is free from zinc or contains less than 0.2% by weight of zinc based on the insulin content of the formulation. 10. The method according to claim 9, wherein the pH is in a range from 6 to 8.5. 11. The method according to claim 9, wherein the formulation further comprises tromethamine. 12. The method according to claim 9, wherein the formulation further comprises NaCl. 13. The method according to claim 9, wherein the formulation further comprises cresol. 14. The method according to claim 13, wherein the formulation further comprises tromethamine. 15. The method according to claim 14, wherein the formulation further comprises NaCl. 16. The method according to claim 9, wherein the compound is polysorbate 20. 17. A method of making a formulation comprising Lys(B3),Glu(B29) human insulin; a compound chosen from polysorbate 20, polysorbate 80, and poloxamer 171; and water, wherein the formulation is free from zinc or contains less than 0.2% by weight of zinc based on the insulin content of the formulation; said method comprising: dissolving the Lys(B3),Glu(B29) human insulin in the water, adding the compound chosen from polysorbate 20, polysorbate 80, and poloxamer 171, and optionally adding a final volume of water. 18. The method according to claim 17, wherein the formulation comprises a pH in a range from 6 to 8.5, and the method comprises: dissolving the Lys(B3),Glu(B29) human insulin in the water, adjusting the pH, adding the compound chosen from polysorbate 20, polysorbate 80, and poloxamer 171, and optionally adding a final volume of water. 19. The method according to claim 17, wherein the compound is polysorbate 20.